GROWTH HORMONE AXIS RESEARCH / MATRIX
Three Peptides, Three Very Different Research Protocols
How CJC-1295, ipamorelin, and MOTS-c differ in mechanism, study design maturity, measured pharmacokinetics, and the single most important caution the literature attaches to each.
The short version
This page lines up CJC-1295, ipamorelin, and MOTS-c on the dimensions that matter most when reading Growth Hormone Axis peptide research: what receptor or mechanism each acts on, how mature and how large the study protocols behind each one are, what pharmacokinetic numbers (like half-life) have actually been measured in humans, and the single biggest caution attached to each compound. The honest summary is uneven: CJC-1295 has small human pharmacokinetic studies but no efficacy trial; ipamorelin has the most complete human trial record of the three, and that trial did not meet its primary endpoint; MOTS-c has almost no human interventional data at all. None of this is medical advice, and no dose is recommended anywhere on this page.
The comparison matrix
| Dimension | CJC-1295 | Ipamorelin | MOTS-c |
|---|---|---|---|
| Primary mechanism | GHRH-receptor (GHRHR) agonist on pituitary somatotrophs [4] | Ghrelin/GHS-R1a receptor agonist, selective for GH release [11] | AMPK activation via CK2 binding and folate-cycle/purine-biosynthesis inhibition [13][17] |
| Longest reported human data | IGF-1 elevation tracked to 28 days post-dose (multi-dose protocol) [4] | Single Phase 2 RCT, up to 7 days of twice-daily dosing [8] | No interventional human data; observational cohort followed a median 26.5 months [14] |
| Measured human half-life | 5.8-8.1 days (estimated, DAC form) [4] | Approximately 2 hours (terminal half-life, IV) [9] | Not established in humans |
| Study-design maturity | Multiple Phase 1 human PK studies; no Phase 2/3 program on record | One completed Phase 2 RCT (primary endpoint not met) [8]; Phase 1 PK study [9]; preclinical work | Cell-culture and rodent studies; human data limited to observational biomarker association [14] |
| Most consistent research finding | Dose-dependent, multi-day GH/IGF-1 elevation replicated across independent PK studies [4][5] | Selective GH release without meaningful ACTH/cortisol elevation, replicated across species [11] | Direct CK2 binding and AMPK-dependent nuclear gene regulation, demonstrated in cells and mice [13][17] |
| Key caution | Sustained IGF-1 elevation (epidemiologic cancer-risk association) and fluid retention | A class-level cardiotoxicity signal from a related (not identical) GHS-R1a agonist [7] | No human pharmacokinetic data exist; rodent-study doses cannot be extrapolated to people |
Primary mechanism
CJC-1295 and ipamorelin both trigger growth hormone release from the pituitary, but through separate receptors — CJC-1295 via the GHRH receptor [4], ipamorelin via the ghrelin/GHS-R1a receptor [11] — which is the pharmacological logic behind studying and, in some research contexts, combining the two [12]. MOTS-c is mechanistically distinct from both: it does not primarily act through a pituitary hormone receptor at all, instead activating AMPK through direct CK2 binding and folate-cycle inhibition, with downstream nuclear gene-expression effects [13][17]. Only CJC-1295 and ipamorelin converge on GH release as a shared endpoint; MOTS-c's connection to the broader GH/IGF-1 axis is comparatively indirect.
Study design and protocol maturity
This is where the three compounds separate most sharply. CJC-1295's human evidence consists of small pharmacokinetic studies — single- and multiple-dose protocols in a few dozen healthy adults tracking GH and IGF-1 over days to weeks [3][4][5] — with no Phase 2 or Phase 3 program identified in the literature. Ipamorelin has the single most complete human protocol of the three: a randomized, controlled Phase 2 trial (NCT00672074) in 114 surgical patients, dosed intravenously twice daily for up to 7 days [8], plus a separate acute-dosing PK study in 8 healthy volunteers [9] — but the Phase 2 trial's primary endpoint did not reach statistical significance. MOTS-c's protocol record is the thinnest by a wide margin: repeated-dosing rodent protocols [13][16] and cell-based mechanistic work [17], with the only human data point being an observational cohort in which no MOTS-c was ever administered [14].
Pharmacokinetics: what's actually been measured
Where PK numbers exist, they diverge sharply by design. CJC-1295's DAC form is engineered for duration — an estimated 5.8-8.1 day elimination half-life, with IGF-1 elevated for up to 28 days after repeated dosing [4]. Ipamorelin is engineered for the opposite: a fast, discrete pulse, with a measured terminal half-life around 2 hours and peak GH response at roughly 40 minutes post-dose [9]. MOTS-c has no published human PK parameters at all — no measured half-life, clearance, or volume of distribution in people — which is a direct consequence of there being no completed human interventional study to measure them in.
Key caution, compound by compound
Each compound's defining caution follows directly from its evidence gap. For CJC-1295, it is the combination of sustained IGF-1 elevation — a hormone epidemiologically linked to modestly higher cancer risk at the population level — with fluid-retention effects that are well documented mechanistically even though CJC-1295-specific long-term outcome data do not exist. For ipamorelin, it is a class-level cardiotoxicity signal: a 28-day preclinical safety study of a different ghrelin-receptor agonist (GSK894281, not ipamorelin) found dose-dependent myocardial degeneration in rats [7], and no equivalent chronic cardiovascular study of ipamorelin itself has been published in any species. For MOTS-c, the caution is structural rather than mechanistic: there is no measured human pharmacokinetic profile, no completed interventional trial, and therefore no basis for translating any rodent-study dose into a human context. Reading the three side by side, the pattern is less about which compound is "riskiest" and more about how unevenly the underlying research protocols have been built out.